| FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE | None | ||
| 0.045MG;0.021MG, 0.115MG;0.021MG, 0.23MG;0.021MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| ADVAIR HFA is indicated for the long-term, twice-daily maintenance treatment of asthma in patients 12 years of age and older. | |||
|
Yes
| |||
| ADVAIR HFA | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 | Patent 23 | Patent 24 | Patent 25 | Patent 26 | Patent 27 | Patent 28 | Patent 29 | Patent 30 | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ********* ********* *** * ********** ****** | ********* ********* *** * ********** ****** | **************** *********** | **************** *********** | **************** *********** ****** β* -************** ********* ********* ****** | **************** *********** | **************** *********** | **************** *********** ****** β* -************** ********* ********* ****** | *********** | *********** | ************** ******* *********** ********** * *********** **********, * ********** *** ************* **** ** * ********** | ************** ******* *********** ********** * *********** **********, * ********** *** ************* **** ** * ********** | ******* ********* *** * ****** *** ******* *** ************** ** * ************* ****** ** * **************** ****** ******* | ******* ************ ********** ********** **** *** *********** ********** | ********* ********** ******* ************ ********** ***** *** *********** ********** | ******* ********* *** * ****** *** ******* *** ************** ** * ************* ****** ** * **************** ****** ******* | ******* ************ ********** ********** **** *** *********** ********** | ********* ********** ******* ************ ********** ***** *** *********** ********** | ******* **** ******* *** ********** | ******* **** ******* *** *********** ********** | ******* **** ******* *** ********** | ******* **** ******* *** *********** ********** | ******* **** ******* *** *********** ********** | ******* **** ******* *** *********** ********** | ***** *** ******* ********* | ***** *** ******* ********* | ***** *** ******* ********* | ***** *** ******* ********* | ********** ****** | ******** ****** *** * ********** *** ****** *** *** ******** ******* | ********** ****** | ********** ****** | ********** ****** | ****** *** ********* *** ********* *** ********** * ************** ***** ** * **** ** ***** ******** ** * ****** ***** | ********* **** *****′ ******* | ********* **** *****' ******* | ***** *** ******* ********* | ***** *** ******* ********* | ***** *** ******* ********* | ***** *** ******* ********* | ********** ****** | ******** ****** *** * ********** *** ****** *** *** ******** ******* | ********** ****** | ********** ****** | ********** ****** | ***** *** ******* ********* | ****** *** ********* *** ********* *** ********** * ************** ***** ** * **** ** ***** ******** ** * ****** ***** | ****** *** ********* *** ********* *** ********** * ************** ***** ** * **** ** ***** ******** ** * ****** ***** | ********* **** *****' ******* | ***** *** ******* ********* | ****** ******* *** ** ******* ********* | ********** ******* ************ | ********** ******* ************ | ********* ********* *** * ********** ****** | ********* ********* *** * ********** ****** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|